Long-term treatment with deupirfenidone (LYT-100) is generally well tolerated and may stabilize lung function in people with idiopathic pulmonary fibrosis (IPF), according to new clinical trial data announced by the therapy’s developer, Puretech Health. Puretech has already met with the U.S. Food and Drug Administration to discuss the Phase 2b trial data, and the company […] The post Deupirfenidone may stabilize lung function in IPF: Long-term data appeared first on Pulmonary Fibrosis News.
